Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: FDA's Division of General and Restorative Devices

This article was originally published in The Gray Sheet

Executive Summary

FDA's Division of General and Restorative Devices: Office of Device Evaluation division assumes responsibility for all neurological device premarket reviews effective Oct. 1. Formerly reviewed by ODE's Division of Cardiovascular, Respiratory and Neurological Devices, responsibility for the products was transferred to DGRD to prevent any overlap of efforts resulting from the restorative nature of the neurological products, FDAers say. Two DCRND reviewers have moved to DGRD, which will spread the added workload among the four existing branches as appropriate...

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts